Brudno, Jennifer N.
Lam, Norris
Vanasse, Danielle
Shen, Yueh-wei
Rose, Jeremy J.
Rossi, John
Xue, Allen
Bot, Adrian
Scholler, Nathalie http://orcid.org/0000-0003-3743-7102
Mikkilineni, Lekha
Roschewski, Mark
Dean, Robert
Cachau, Raul http://orcid.org/0000-0001-9260-2102
Youkharibache, Philippe
Patel, Rashmika
Hansen, Brenna
Stroncek, David F.
Rosenberg, Steven A.
Gress, Ronald E.
Kochenderfer, James N. http://orcid.org/0000-0002-4362-9875
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (ZIA BC011417-08)
Article History
Received: 12 September 2019
Accepted: 10 December 2019
First Online: 20 January 2020
Change Date: 14 April 2020
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-020-0864-x
Competing interests
: This work was supported by intramural funding of the Center for Cancer Research, NCI, NIH. In addition, the NCI has cooperative research and development agreements with Kite Pharma, a Gilead Company that supports development of anti-CD19 CAR T-cell therapies, and both J.N.K. and S.A.R. are NCI principal investigators of these research agreements. J.K. has a patent application for the Hu19-CD828Z CAR and has received royalty payments from Kite, a Gilead Company. A.B., J.R., A.X. and N.S. are all employees of Kite, a Gilead Company.